BPG is committed to discovery and dissemination of knowledge
Prospective Study
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Sep 15, 2026; 18(9): 120559
Published online Sep 15, 2026. doi: 10.4251/wjgo.120559
Figure 5
Figure 5 Compare the performance of 18F-fluorodeoxyglucose and 18F-fibroblast activation protein inhibitor-04 positron emission tomography in detecting primary tumors, lymph nodes, bone and peritoneal metastases, local recurrences. Data are presented descriptively without statistical hypothesis testing. No P values are shown. LNM: Lymph node metastases; Mets: Metastases; Recs: Recurrences; PET/CT: Positron emission tomography/computed tomography; 18F-FAPI: 18F-fibroblast activation protein inhibitor; 18F-FDG: 18F-fluorodeoxyglucose.


Write to the Help Desk